Insights

Expanding Diagnostic Portfolio Mirxes is actively building a comprehensive cancer detection portfolio including early detection tests for multiple cancer types such as lung, thyroid, colorectal, breast, liver, and ovarian cancer. This presents an opportunity to offer advanced diagnostic solutions and biomarker discovery tools to healthcare providers and laboratories involved in cancer screening and early diagnosis.

Global Market Reach With operations in Singapore, USA, Japan, and China, and a distribution network that exports to over 45 countries, Mirxes is well-positioned to expand its sales presence. Partnering with regional distributors or healthcare institutions can accelerate market penetration for its cutting-edge molecular diagnostic tests.

Innovative Technology Platform Mirxes has developed a versatile miRNA technology platform, mSMRT-qPCR, which can be applied across various disease areas including cardiovascular and infectious diseases. Sales efforts can focus on licensing or selling this platform to biotech firms and diagnostic labs seeking high-precision microRNA detection tools.

Recent Funding and IPO Potential Recent investments and a significant IPO target of at least US$100 million indicate strong growth traction and investor confidence. This financial backing provides resources to scale manufacturing, R&D, and sales activities, opening opportunities to collaborate with large hospital networks and research institutions.

Public Health and COVID-19 Experience Mirxes' successful mass production of COVID-19 tests and deployment across numerous hospitals demonstrates its capability to meet large-scale diagnostic needs. This track record can be leveraged to promote enterprise-level diagnostic solutions to government health agencies and large healthcare organizations seeking reliable testing infrastructure.

MiRXES Tech Stack

MiRXES uses 8 technology products and services including Punycode, React, jQuery Migrate, and more. Explore MiRXES's tech stack below.

  • Punycode
    Font Scripts
  • React
    Javascript Frameworks
  • jQuery Migrate
    Javascript Libraries
  • jQuery Mobile
    Mobile Frameworks
  • Yoast SEO
    Search Engines
  • YouTube
    Video Players
  • GoDaddy
    Web Hosting
  • jQuery Validation Plugin
    Web Tools And Plugins

Media & News

MiRXES's Email Address Formats

MiRXES uses at least 1 format(s):
MiRXES Email FormatsExamplePercentage
FirstLast@mirxes.comJohnDoe@mirxes.com
71%
FirstMiddleLast@mirxes.comJohnMichaelDoe@mirxes.com
12%
FirstLas@mirxes.comJohnDoe@mirxes.com
9%
First.Last@mirxes.comJohn.Doe@mirxes.com
8%

Frequently Asked Questions

Where is MiRXES's headquarters located?

Minus sign iconPlus sign icon
MiRXES's main headquarters is located at 2 Tukang Innovation Grove, JTC MedTech Hub, #09-02, Singapore, 618305, SG. The company has employees across 2 continents, including AsiaNorth America.

What is MiRXES's official website and social media links?

Minus sign iconPlus sign icon
MiRXES's official website is mirxes.com and has social profiles on LinkedInCrunchbase.

What is MiRXES's SIC code NAICS code?

Minus sign iconPlus sign icon
MiRXES's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does MiRXES have currently?

Minus sign iconPlus sign icon
As of December 2025, MiRXES has approximately 201 employees across 2 continents, including AsiaNorth America. Key team members include Chief Executive Officer: Y. W.Cto: Z. R.Chief Investor Relations Officer: M. L.. Explore MiRXES's employee directory with LeadIQ.

What industry does MiRXES belong to?

Minus sign iconPlus sign icon
MiRXES operates in the Biotechnology Research industry.

What technology does MiRXES use?

Minus sign iconPlus sign icon
MiRXES's tech stack includes PunycodeReactjQuery MigratejQuery MobileYoast SEOYouTubeGoDaddyjQuery Validation Plugin.

What is MiRXES's email format?

Minus sign iconPlus sign icon
MiRXES's email format typically follows the pattern of FirstLast@mirxes.com. Find more MiRXES email formats with LeadIQ.

How much funding has MiRXES raised to date?

Minus sign iconPlus sign icon
As of December 2025, MiRXES has raised $77M in funding. The last funding round occurred on Jul 08, 2021 for $77M.

When was MiRXES founded?

Minus sign iconPlus sign icon
MiRXES was founded in 2014.

MiRXES

Biotechnology ResearchSingapore201-500 Employees

Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum.

We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide.

Our flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers. 

We continue to build a comprehensive cancer portfolio with early detection tests for lung and thyroid cancer (2022), colorectal and breast cancer (2023), liver and ovarian cancer (2024). We are concurrently building a precision oncology portfolio to provide clinical insights for the complete patient journey.

MiRXES was spun off from A*STAR’s Bioprocessing Technology Institute in 2014 to commercialize an industry-leading qPCR-based technology for microRNA detection. Our ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.

Our versatile platform technology and capabilities have broad applications in the discovery of biomarkers and diagnosis of diseases. We are starting with early cancer detection, but we will also be addressing unmet clinical needs in cardiovascular, metabolic, and infectious diseases.

We responded to COVID-19 by leveraging our capabilities to mass produce and distribute over 5 million units of the Fortitude COVID-19 RT-PCR test. This made-in-Singapore diagnostic test, developed by A*STAR and Tan Tock Seng Hospital, has been deployed in 13 Singapore hospitals and clinical labs and exported to over 45 countries worldwide. Post-COVID, we will leverage this network to commercialize multi-cancer early detection tests.

Section iconCompany Overview

Headquarters
2 Tukang Innovation Grove, JTC MedTech Hub, #09-02, Singapore, 618305, SG
Website
mirxes.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
201-500

Section iconFunding & Financials

  • $77M

    MiRXES has raised a total of $77M of funding over 1 rounds. Their latest funding round was raised on Jul 08, 2021 in the amount of $77Mas a Series C.

  • $250M$500M

    MiRXES's revenue is estimated to be in the range of $250M$500M

Section iconFunding & Financials

  • $77M

    MiRXES has raised a total of $77M of funding over 1 rounds. Their latest funding round was raised on Jul 08, 2021 in the amount of $77Mas a Series C.

  • $250M$500M

    MiRXES's revenue is estimated to be in the range of $250M$500M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.